Note 4 - Inventory

6 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Inventory Disclosure [Text Block]

4. Inventory

Inventory consisted of the following at

December 31, 2019 

and

June 30, 2019 (

in thousands):

	December 31,		June 30,
	2019		2019
Raw materials	$	372	$	333
Work in process		166		166
Finished goods		7		31
Total inventory, current	$	545	$	530

	December 31,		June 30,
	2019		2019
Enriched barium, non-current	$	116	$	117
Raw materials, non-current		11		38
Total inventory, non-current	$	127	$	155

Inventory, non-current represents raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will

not

be consumed within an operating cycle. On 

August 25, 2017, 

the Company entered into a Consignment Agreement and related Services Agreement with MedikorPharma-Ural LLC to begin utilizing our enriched barium-

130

 carbonate inventory. The Company originally anticipated obtaining enough Cesium-

131

 under this arrangement to obtain over 

4,000

 curies of Cesium-

131.

During the

three

and

six

months ended

December 31, 2019,

the Company obtained

no

and

31

 curies, respectively, of Cesium-

131

 under this agreement which has been used in production. At

December 31, 2019,

the Company estimates that the remaining enriched barium will result in

894

curies; approximately

60

of which will be obtained in the next

twelve

months and

834

 will be obtained after

December 31, 2020.

There is 

no

 assurance as to whether the agreement will be terminated before this full amount is obtained and other supply sources are used, nor is there assurance that the agreements with the 

third

-party Cesium-

131

 suppliers will be executed.